Keros Therapeutics (NASDAQ:KROS) Lowered to “Neutral” Rating by Guggenheim

Keros Therapeutics (NASDAQ:KROS) was downgraded by investment analysts at Guggenheim from a “buy” rating to a “neutral” rating in a research report issued on Monday, Marketbeat reports.

Other equities analysts have also recently issued reports about the stock. Bank of America decreased their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. TD Cowen downgraded Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Wells Fargo & Company increased their target price on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $81.33.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $18.00 on Monday. The firm has a market capitalization of $729.13 million, a PE ratio of -3.45 and a beta of 1.20. Keros Therapeutics has a one year low of $15.67 and a one year high of $73.00. The stock’s 50 day moving average price is $57.46 and its 200 day moving average price is $52.30.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company’s quarterly revenue was up 4750.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.33) earnings per share. On average, analysts forecast that Keros Therapeutics will post -5.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. KBC Group NV boosted its position in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares during the last quarter. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics in the third quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Keros Therapeutics during the 2nd quarter valued at $128,000. Finally, LMR Partners LLP bought a new stake in shares of Keros Therapeutics during the 3rd quarter worth $213,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.